Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed
Completed · Phase 3 · Has a placebo group
Conditions studied: HIV-1-infection
In brief
The primary objective of this study is to evaluate the efficacy of switching from a regimen of either dolutegravir (DTG) and emtricitabine /tenofovir alafenamide (F/TAF) or DTG and emtricitabine/tenofovir disoproxil fumarate (F/TDF) to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus DTG+F/TAF in virologically suppressed HIV-1 infected adults with or without antiretroviral (ARV) resistance.
Key facts
- Study ID
- NCT03110380
- Run by
- Gilead Sciences
- People needed
- 567
- Starts
- 2017-06-12
- Expected to finish
- 2021-02-10
- Last updated by the study team
- 2022-01-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Ruane Clinical Research Group Inc. — Los Angeles, California, United States
- Mills Clinical Research — Los Angeles, California, United States
- Highland Hospital - Alameda Health System — Oakland, California, United States
- Cares Community Health — Sacramento, California, United States
- Kaiser Permanente — Sacramento, California, United States
- Hepatitis/HIV Clinical Trials Group (HHCTG) — San Francisco, California, United States
- Kaiser Permanente — San Francisco, California, United States
- Kaiser Permanente, Department of Infectious Diseases — San Leandro, California, United States
- University of Colorado Denver, University of Colorado Hospital — Aurora, Colorado, United States
- Whitman-Walker Institute — Washington D.C., District of Columbia, United States
- Dupont Circle Physician's Group — Washington D.C., District of Columbia, United States
- Providence Hospital Center for Infectious Diseases — Washington D.C., District of Columbia, United States
- The GW Medical Faculty Associates — Washington D.C., District of Columbia, United States
- Midland Florida Clinical Research Center, LLC — DeLand, Florida, United States
- Therafirst Medical Center — Fort Lauderdale, Florida, United States
- Gary J. Richmond, M.D., P.A. — Fort Lauderdale, Florida, United States
- Midway Immunology and Research Center — Ft. Pierce, Florida, United States
- University of Miami Divison of Infectious Diseases Clinical Research Unit — Miami, Florida, United States
- AIDS Healthcare Foundation - South Beach — Miami Beach, Florida, United States
- Orlando Immunology Center — Orlando, Florida, United States
- AHF-Pensacola — Pensacola, Florida, United States
- Infectious Disease Research Institute Inc — Tampa, Florida, United States
- St. Joseph's Hospital Comprehensive Research Institute — Tampa, Florida, United States
- AIDS Research and Treatment Center of the Treasure Coast — Vero Beach, Florida, United States
- Spectrum Medical Group — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.